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LETTER TO THE EDITOR
Fig. 1. Clinical presentation on admission.
Etanercept in the Treatment of Generalized Annular 
Pustular Psoriasis
Ada Lo Schiavo, M.D., Gabriella Brancaccio, M.D., Rosa Valentina Puca, M.D., Stefano Caccavale, M.D.
Department of Dermatology, Second University of Naples, Naples, Italy  
To the Editor:
Pustular psoriasis is a rare form of psoriasis characterized 
by an eruption of sterile pustules. It can be divided into 
both generalized and localized forms
1. Some authors 
consider a separate variant of generalized psoriasis, well 
described by Lapière, as recurrent circinate erythematous 
psoriasis. It presents with erythematous, annular or 
polycyclic lesions, and an eruption of small sterile 
pustules and fine desquamation. The patches extend from 
the center and resolve within some weeks, leaving scales 
and changes in pigmentation and pigmentary changes. 
Frequent relapses are described in the bordering areas
2,3. 
In this study, we report the case of a woman affected by 
generalized annular pustular (Lapière) psoriasis. This 
patient had previously been treated with conventional 
therapeutics, and demonstrated a significant improvement 
after treatment with etanercept. This 70-year-old Cauca-
sian woman, described in our report, has a 35-year history 
of psoriasis. Physical examination revealed the presence 
of small erythematous papules, centered by a pustule, a 
few millimeters in diameter (Fig. 1). Histological exami-
nation showed Kogoj-Lapière spongiform multilocular 
typical pustules (an epidermal pustule formed by infiltra-
tion of neutrophils into necrotic areas of the epidermis, 
where the cell walls form a swampy network), features 
compatible with the clinical diagnosis of Lapière psoriasis. 
The patient had previously been treated with other topical 
and systemic drugs (colchicine, acitretin, ciclosporin, 
methotrexate) and ultraviolet B narrow band photo-
therapy, with partial and temporary benefits, side effects, 
and frequent relapses. Differential diagnosis of our case 
included other generalized pustular psoriasis: acute gene-
ralized exanthematous pustolosis (AGEP) was perhaps the 
most important differential diagnosis. AGEP, which occurs 
as an acute, spontaneously healling reaction to drugs 
(usually antibiotics), was excluded on the basis of the 
absence of vasculitis associated with spongiform pustules 
and based on the presence of psoriatic anamnesis. Lapière 
psoriasis can be differentiated from pustular lesions 
caused by prolonged application of topical steroids or tar 
ointments on the periphery of pre-existent psoriatic 
plaques. Unlike the Von Zumbusch generalized form, the 
general state of health is not compromised. 
The patient was treated with 50 mg of etanercept twice 
weekly subcutaneously for three months. There was an AL Schiavo, et al
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Fig. 2. Complete clearance of the pustular eruption after etanercept
treatment.
extremely rapid response, noticeable from the second day, 
with complete clearance of the pustular eruption at the 
end of the first week. At week 12 of etanercept treatment, 
complete clearance of cutaneous lesion was achieved (Fig. 
2), including erythema and scaling, with no significant 
side effects reported, concomitant infections, decreased 
blood granulocytes or other laboratory changes. Main-
tenance treatment with 50 mg of etanercept once a week 
subcutaneously was continued for another three months. 
No relapse was noted at week 35.    
There are no universally accepted guidelines for manage-
ment of Lapière psoriasis; no clinical trials have been 
conducted and no single agent has been approved for this 
indication. Only case reports or short series of patients 
have been published on the off-label use of biologic drugs 
for pustular psoriasis
4,5. In contrast, de novo paradoxical 
pustular flares induced by anti-tumor necrosis factor 
(anti-TNF-α) therapy have been described
6. 
Etanercept is a soluble recombinant human tumor necrosis 
factor α (TNF-α) receptor that acts as a competitive inhi-
bitor of TNF-α  by binding to and inactivating endogenous 
TNF-α, thereby preventing its interactions with cell 
surface receptors
7. Based on our experience, etanercept 
may be an effective therapeutic option in the treatment of 
Lapière psoriasis. In fact, in our patient, etanercept 
demonstrated a high efficacy with a rapid and significant 
clinical response associated with an excellent safety 
profile. The rapid clearance, the good maintenance of 
efficacy and the excellent tolerability suggest a role for 
etanercept in the management of Lapière psoriasis, 
especially in elderly patients with typical pathologies. 
Specifically, this may apply if other treatment modalities 
are contraindicated or proven to be ineffective.  
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